



<b>HHCP-I Human Hepatocytes Cryopreserved Plateable for Induction assays Cell Specification – Certificate of Analysis (CoA)</b>	
Lot HH230404	Batch Release: May 28, 2024

Donor data	
Species: Human	Gender: female Age: 64 years
Diagnosis: CCC (Cholangiocellular carcinoma) Medical History: Hypertension	Therapy: Hemihepatectomy right Medication: Asthmaspray Serology: HAV, HBV, HCV, HIV 1/2: negative

Cryopreservation and Thawing	
<b>Cryopreservation:</b> Date: Apr 04, 2023 Amount per vial: 10.0 x 10 <sup>6</sup> cells	<b>Thawing:</b> n=2 Post-thaw viability: 90.5 ± 2.2 % Post-thaw yield per vial: 5.6 ± 0.6 x 10 <sup>6</sup> cells Recovery: 56.0 ± 6.1 %

2D culture	
Phase contrast on day 1 after thawing (24well plate)	Phase contrast on day 3 after thawing (24well plate)
	

Recommended seeding density on collagen-coated plates:  
24well plate – 400,000 cells/well // 96well plate – 70,000 cells/well.  
Culture in Human Hepatocyte Maintenance Medium (HHMM).

CYP P450 activity in 2D culture after thawing: Ethoxyresorufin-O-deethylation: Induction with 25 µM β-Naphthoflavone	pmol/(mg × min) 24well: 6.1 ± 0.2 96well: 11.9 ± 3.2	X-fold induction 4.5 4.1
--	--	--------------------------------

### Suspension culture

Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5 x 10<sup>6</sup> cells in 0.5 ml HPM-Cryo):

Time (h)	0.5	1	1.5	2	3	4	5
Viability (%)	81.7	78.4 ± 0.5	83.9	78.5 ± 6.0	79.9 ± 3.8	84.4 ± 1.3	77.2 ± 3.6

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

**Store at -150 °C or in the vapour phase of LN<sub>2</sub>**

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: A. Alkufairi	Verified by: K. Damrau
-------------------------	------------------------